Brant Point Investment Management LLC boosted its holdings in shares of Syneos Health Inc (NASDAQ:SYNH) by 63.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,016 shares of the company’s stock after buying an additional 73,300 shares during the period. Syneos Health makes up 0.9% of Brant Point Investment Management LLC’s holdings, making the stock its 11th largest position. Brant Point Investment Management LLC owned approximately 0.18% of Syneos Health worth $9,744,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in the stock. Hsbc Holdings PLC increased its position in Syneos Health by 18.0% during the 3rd quarter. Hsbc Holdings PLC now owns 7,417 shares of the company’s stock valued at $382,000 after buying an additional 1,131 shares in the last quarter. Trillium Asset Management LLC increased its holdings in shares of Syneos Health by 3.5% in the third quarter. Trillium Asset Management LLC now owns 37,403 shares of the company’s stock valued at $1,928,000 after purchasing an additional 1,257 shares during the period. BB&T Corp increased its holdings in shares of Syneos Health by 26.7% in the third quarter. BB&T Corp now owns 6,602 shares of the company’s stock valued at $341,000 after purchasing an additional 1,393 shares during the period. Louisiana State Employees Retirement System increased its holdings in shares of Syneos Health by 10.7% in the third quarter. Louisiana State Employees Retirement System now owns 16,600 shares of the company’s stock valued at $856,000 after purchasing an additional 1,600 shares during the period. Finally, Advisors Asset Management Inc. increased its holdings in shares of Syneos Health by 12.0% in the second quarter. Advisors Asset Management Inc. now owns 17,216 shares of the company’s stock valued at $362,000 after purchasing an additional 1,841 shares during the period.
A number of brokerages have recently weighed in on SYNH. William Blair raised Syneos Health from a “market perform” rating to an “outperform” rating in a report on Friday, October 19th. KeyCorp increased their price objective on Syneos Health from $54.00 to $59.00 and gave the company an “overweight” rating in a report on Friday, August 10th. ValuEngine lowered Syneos Health from a “hold” rating to a “sell” rating in a report on Thursday, September 6th. Zacks Investment Research raised Syneos Health from a “hold” rating to a “buy” rating and set a $56.00 price objective on the stock in a report on Tuesday, November 20th. Finally, Evercore ISI began coverage on Syneos Health in a report on Thursday, October 4th. They issued an “outperform” rating and a $58.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Syneos Health has an average rating of “Buy” and an average price target of $54.70.
Syneos Health (NASDAQ:SYNH) last posted its earnings results on Tuesday, November 6th. The company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.58 by $0.17. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.12 billion. Syneos Health had a positive return on equity of 8.67% and a negative net margin of 0.84%. The firm’s revenue for the quarter was up 88.3% on a year-over-year basis. Research analysts anticipate that Syneos Health Inc will post 2.47 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2018/12/02/syneos-health-inc-synh-position-lifted-by-brant-point-investment-management-llc.html.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
See Also: Capital Gains
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.